On the 13th of January 2022, the European Commission (EC), the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have launched a new initiative named Accelerating Clinical Trials in the EU" (ACT EU).
The initiative aims to straighten the European environment for Clinical Trials by promoting the development of high quality, safe and effective medicines and maintaining the protection of the participants, data quality and transparency.
The designed strategy for 2022-2023 includes a priority action for the establishment of a multistakeholder platform, where the community, including ERNs, can collaborate.